目的:探讨支气管扩张患者联合应用头孢哌钠酮舒巴坦钠与盐酸左氧氟沙星对其疗效及血清炎性因子(CRP、白细胞介素-6)的影响。方法:选取河南宏力医院2022年10月至2023年10月收治的86例支气管扩张患者为研究对象,根据随机数字表法分别纳入...目的:探讨支气管扩张患者联合应用头孢哌钠酮舒巴坦钠与盐酸左氧氟沙星对其疗效及血清炎性因子(CRP、白细胞介素-6)的影响。方法:选取河南宏力医院2022年10月至2023年10月收治的86例支气管扩张患者为研究对象,根据随机数字表法分别纳入盐酸左氧氟沙星治疗的患者为对照组43例和基于对照组接受头孢哌钠酮舒巴坦钠治疗的患者为研究组43例。比较两组临床疗效,探讨不同分组患者临床症状改善情况,对比治疗前后不同分组患者的炎性因子及肺功能相关指标水平差异统计治疗期间用药不良反应的发生情况。结果:与对照组相比,研究组临床治疗总有效率93.02%显著更高,临床症状消失时长显著更短(P<0.05),降钙素原(procalcitonin, PCT)、白细胞介素-6(interleukin-6,IL-6)、C反应蛋白(C-reactive protein, CRP)、红细胞沉降率(erythrocyte sedimentation rate, ESR)等炎性因子水平显著更低,用力肺活量(forced vital capacity, FVC)、第1秒用力呼气容积(forced expiratory volume in one second, FEV1)、FEV1占预计值百分比值(forced expiratory volume in one second predicted, FEV1%)、FEV1与FVC的百分比值(forced expiratory volume in one second/forced vital capacity, FEV1/FVC)等肺功能相关指标水平显著更高(P<0.05);较之治疗前,治疗后两组PCT、IL-6、CRP、ESR等炎症因子水平显著更低(P<0.05),FVC、FEV1、FEV1%、FEV1/FVC等肺功能相关指标水平显著更高(P<0.05)。且研究组治疗期间用药不良反应发生率13.96%与对照组11.64%比较无统计学意义(P>0.05)。结论:支气管扩张患者采取头孢哌钠酮舒巴坦钠与盐酸左氧氟沙星联合用药方案,临床疗效显著,不仅可有效缩短其临床症状消失时间,在降低患者机体内炎症因子水平、改善其肺功能方面也具有明显积极作用,且并不会增加用药不良反应发生风险,安全性良好。展开更多
To develop near-infrared （NIR） reflectance spectroscopic methods for the quantitative analysis of cefoperazone sodium/ sulbactam sodium from different manufacturers for injection powder medicaments. Various powders ...To develop near-infrared （NIR） reflectance spectroscopic methods for the quantitative analysis of cefoperazone sodium/ sulbactam sodium from different manufacturers for injection powder medicaments. Various powders of cefoperazone sodium/ sulbactam sodium were directly analyzed by non-destructive NIR reflectance spectroscopy using the spectrometer EQUINOX55. Two quantitative methods via integrating sphere （IS） and fiberoptic probe （FOP） models were explored from 6 batches of commercial samples and 42 batches of laboratory samples at a content ranging from 30% to 70% for cefoperazone and 60% to 20% for sulbactam. The root mean square errors of cross validation （RMSECV） and the root mean square errors of prediction （RMSEP） of IS were 1.79% and 2.85%, respectively, for cefoperazone sodium, and were 1.86% and 3.08%, respectively, for sulbactam sodium; and those of FOP were 2.93% and 2.92%, respectively, for cefoperazone sodium, and were 2.23% and 3.01%, respectively, for sulbactam sodium. Based on the ICH guidelines and Ref. 12, the quantitative models were then evaluated in terms of specificity, linearity, accuracy, precision, robustness and model transferability. The non-destructive quantitative NIR methods used in this study are applicable for rapid analysis of injectable powdered drugs from different manufacturers.展开更多
文摘目的:探讨支气管扩张患者联合应用头孢哌钠酮舒巴坦钠与盐酸左氧氟沙星对其疗效及血清炎性因子(CRP、白细胞介素-6)的影响。方法:选取河南宏力医院2022年10月至2023年10月收治的86例支气管扩张患者为研究对象,根据随机数字表法分别纳入盐酸左氧氟沙星治疗的患者为对照组43例和基于对照组接受头孢哌钠酮舒巴坦钠治疗的患者为研究组43例。比较两组临床疗效,探讨不同分组患者临床症状改善情况,对比治疗前后不同分组患者的炎性因子及肺功能相关指标水平差异统计治疗期间用药不良反应的发生情况。结果:与对照组相比,研究组临床治疗总有效率93.02%显著更高,临床症状消失时长显著更短(P<0.05),降钙素原(procalcitonin, PCT)、白细胞介素-6(interleukin-6,IL-6)、C反应蛋白(C-reactive protein, CRP)、红细胞沉降率(erythrocyte sedimentation rate, ESR)等炎性因子水平显著更低,用力肺活量(forced vital capacity, FVC)、第1秒用力呼气容积(forced expiratory volume in one second, FEV1)、FEV1占预计值百分比值(forced expiratory volume in one second predicted, FEV1%)、FEV1与FVC的百分比值(forced expiratory volume in one second/forced vital capacity, FEV1/FVC)等肺功能相关指标水平显著更高(P<0.05);较之治疗前,治疗后两组PCT、IL-6、CRP、ESR等炎症因子水平显著更低(P<0.05),FVC、FEV1、FEV1%、FEV1/FVC等肺功能相关指标水平显著更高(P<0.05)。且研究组治疗期间用药不良反应发生率13.96%与对照组11.64%比较无统计学意义(P>0.05)。结论:支气管扩张患者采取头孢哌钠酮舒巴坦钠与盐酸左氧氟沙星联合用药方案,临床疗效显著,不仅可有效缩短其临床症状消失时间,在降低患者机体内炎症因子水平、改善其肺功能方面也具有明显积极作用,且并不会增加用药不良反应发生风险,安全性良好。
基金National Key Technologies R&D Program Foundation of China (Grant No. 2006BAK04A11)
文摘To develop near-infrared （NIR） reflectance spectroscopic methods for the quantitative analysis of cefoperazone sodium/ sulbactam sodium from different manufacturers for injection powder medicaments. Various powders of cefoperazone sodium/ sulbactam sodium were directly analyzed by non-destructive NIR reflectance spectroscopy using the spectrometer EQUINOX55. Two quantitative methods via integrating sphere （IS） and fiberoptic probe （FOP） models were explored from 6 batches of commercial samples and 42 batches of laboratory samples at a content ranging from 30% to 70% for cefoperazone and 60% to 20% for sulbactam. The root mean square errors of cross validation （RMSECV） and the root mean square errors of prediction （RMSEP） of IS were 1.79% and 2.85%, respectively, for cefoperazone sodium, and were 1.86% and 3.08%, respectively, for sulbactam sodium; and those of FOP were 2.93% and 2.92%, respectively, for cefoperazone sodium, and were 2.23% and 3.01%, respectively, for sulbactam sodium. Based on the ICH guidelines and Ref. 12, the quantitative models were then evaluated in terms of specificity, linearity, accuracy, precision, robustness and model transferability. The non-destructive quantitative NIR methods used in this study are applicable for rapid analysis of injectable powdered drugs from different manufacturers.
